REGN7461
Phase 2
RegeneronREGN7461 is one of 93 therapeutic programs targeting Cutaneous Melanoma. It is currently in Phase 2.
2
Indications
0
Total Trials
0
Active Trials
92
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
91 competitors in Cutaneous Melanoma
#DrugCompanyPhaseTrials
1Tafinlar
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
DTIC-Dome
BayerPhase 3
Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Intron a
Merck & Co.Phase 3
PEG-Intron
Merck & Co.Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Amtagvi
IIovance Biotherapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for REGN7461. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company